Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2011, Article ID 970424, 9 pages
http://dx.doi.org/10.1155/2011/970424
Research Article

Mucosal Immunization Induces a Higher Level of Lasting Neutralizing Antibody Response in Mice by a Replication-Competent Smallpox Vaccine: Vaccinia Tiantan Strain

1AIDS Center and Modern Virology Research Center, State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Hubei 430072, China
2AIDS Institute, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong
3Department of Microbiology and Research Center for Infection and Immunity, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong

Received 23 February 2011; Revised 18 April 2011; Accepted 19 April 2011

Academic Editor: Young-Chul Sung

Copyright © 2011 Bin Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. A. Fulginiti, A. Papier, J. M. Lane, J. M. Neff, and D. A. Henderson, “Smallpox vaccination: a review, part II. Adverse events,” Clinical Infectious Diseases, vol. 37, no. 2, pp. 251–271, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. S. D. Nafziger, “Smallpox,” Critical Care Clinics, vol. 21, no. 4, pp. 739–746, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. D. A. Henderson, “The eradication of smallpox,” Scientific American, vol. 235, no. 4, pp. 25–33, 1976. View at Google Scholar · View at Scopus
  4. M. A. Sauri, J. A. Frelinger, M. L. Garba, R. B. Belshe, and S. E. Frey, “Responses to smallpox vaccine,” The New England Journal of Medicine, vol. 347, no. 9, pp. 689–690, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. D. L. Heymann, “Smallpox containment updated: considerations for the 21st century,” International Journal of Infectious Diseases, vol. 8, supplement 2, pp. S15–S20, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. I. J. Amanna, I. Messaoudi, and M. K. Slifka, “Protective immunity following vaccination: how is it defined?” Human Vaccines, vol. 4, no. 4, pp. 316–319, 2008. View at Google Scholar · View at Scopus
  7. I. J. Amanna, N. E. Carlson, and M. K. Slifka, “Duration of humoral immunity to common viral and vaccine antigens,” The New England Journal of Medicine, vol. 357, no. 19, pp. 1903–1915, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. I. J. Amanna, M. K. Slifka, and S. Crotty, “Immunity and immunological memory following smallpox vaccination,” Immunological Reviews, vol. 211, pp. 320–337, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Mahalingam, I. K. Damon, and B. A. Lidbury, “25 years since the eradication of smallpox: why poxvirus research is still relevant,” Trends in Immunology, vol. 25, no. 12, pp. 636–639, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Weltzin, J. Liu, K. V. Pugachev et al., “Clonal vaccinia virus grown in cell culture as a new smallpox vaccine,” Nature Medicine, vol. 9, no. 9, pp. 1125–1130, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. X. Tang and Z. Chen, “The development of an AIDS mucosal vaccine,” Viruses, vol. 1, no. 2, pp. 283–297, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Fenner, D. A. Henderson, I. Arita, Z. Jezek, and I. D. Ladnyi, Smallpox and Its Eradication, World Health Organization, Geneva, Switzerland, 1988.
  13. S. L. Dong, Q. C., “The founder of vaccinia virus Tiantan strain,” Weishengwuxue Mianyixue Jinzhan, vol. 37, no. 3, pp. 1–3, 2009. View at Google Scholar
  14. W. Yu, Q. Fang, W. Zhu et al., “One time intranasal vaccination with a modified vaccinia Tiantan strain MVTT(ZCI) protects animals against pathogenic viral challenge,” Vaccine, vol. 28, no. 9, pp. 2088–2096, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Kretzschmar, J. Wallinga, P. Teunis, S. Xing, and R. Mikolajczyk, “Frequency of adverse events after vaccination with different vaccinia strains,” PLoS Medicine, vol. 3, no. 8, article e272, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. Q. Fang, L. Yang, W. Zhu et al., “Host range, growth property, and virulence of the smallpox vaccine: vaccinia virus Tian Tan strain,” Virology, vol. 335, no. 2, pp. 242–251, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. X. Huang, B. Lu, W. Yu et al., “A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination,” PLoS One, vol. 4, no. 1, Article ID e4180, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. D. C. Tscharke, P. C. Reading, and G. L. Smith, “Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes,” Journal of General Virology, vol. 83, part 8, pp. 1977–1986, 2002. View at Google Scholar · View at Scopus
  19. H. Liu, W. Yu, X. Tang et al., “The route of inoculation determines the tissue tropism of modified vaccinia Tiantan expressing the spike glycoprotein of SARS-CoV in mice,” Journal of Medical Virology, vol. 82, no. 5, pp. 727–734, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. X. Huang, L. Liu, L. Ren, C. Qiu, Y. Wan, and J. Xu, “Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses,” Vaccine, vol. 25, no. 52, pp. 8874–8884, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. W. K. Joklik, “The purification of four strains of poxvirus,” Virology, vol. 18, no. 1, pp. 9–18, 1962. View at Google Scholar · View at Scopus
  22. Z. Chen, L. Zhang, C. Qin et al., “Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region,” Journal of Virology, vol. 79, no. 5, pp. 2678–2688, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Tsai, C. Caillet, H. Hu et al., “Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase,” Vaccine, vol. 27, no. 48, pp. 6777–6790, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. P. L. Earl, J. L. Americo, and B. Moss, “Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein,” Journal of Virology, vol. 77, no. 19, pp. 10684–10688, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. M. R. E. Benhnia, M. M. McCausland, H. P. Su et al., “Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine,” Journal of Virology, vol. 82, no. 7, pp. 3751–3768, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Edghill-Smith, H. Golding, J. Manischewitz et al., “Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus,” Nature Medicine, vol. 11, no. 7, pp. 740–747, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Fazilleau, M. D. Eisenbraun, L. Malherbe et al., “Lymphoid reservoirs of antigen-specific memory T helper cells,” Nature Immunology, vol. 8, no. 7, pp. 753–761, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. J. M. Neff, L. J. Michael, V. A. Fulginiti, and D. A. Henderson, “Contact vaccinia—transmission of vaccinia from smallpox vaccination,” Journal of the American Medical Association, vol. 288, no. 15, pp. 1901–1905, 2002. View at Google Scholar · View at Scopus
  29. H. L. Robinson, D. C. Montefiori, R. P. Johnson et al., “Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations,” Nature Medicine, vol. 5, no. 5, pp. 526–534, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. J. T. Snyder, I. M. Belyakov, A. Dzutsev, F. Lemonnier, and J. A. Berzofsky, “Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses,” Journal of Virology, vol. 78, no. 13, pp. 7052–7060, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. W. Kastenmuller, G. Gasteiger, L. Stross, D. H. Busch, and I. Drexler, “Cutting edge: mucosal application of a lyophilized viral vector vaccine confers systemic and protective immunity toward intracellular pathogens,” Journal of Immunology, vol. 182, no. 5, pp. 2573–2577, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Elst, “The transmission mechanism of smallpox,” Ärztliche Forschung, vol. 9, no. 1, pp. 13–32, 1955. View at Google Scholar · View at Scopus
  33. I. M. Belyakov, D. Isakov, Q. Zhu, A. Dzutsev, D. Klinman, and J. A. Berzofsky, “Enhancement of CD8+ T cell immunity in the lung by CpG oligodeoxynucleotides increases protective efficacy of a modified vaccinia Ankara vaccine against lethal poxvirus infection even in a CD4-deficient host,” Journal of Immunology, vol. 177, no. 9, pp. 6336–6343, 2006. View at Google Scholar · View at Scopus
  34. I. M. Belyakov, P. Earl, A. Dzutsev et al., “Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 16, pp. 9458–9463, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. I. M. Belyakov, B. Moss, W. Strober, and J. A. Berzofsky, “Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 8, pp. 4512–4517, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Naito, Y. Kaneko, and D. Kozbor, “Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization,” Journal of General Virology, vol. 88, part 1, pp. 61–70, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Ranasinghe, J. C. Medveczky, D. Woltring et al., “Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1,” Vaccine, vol. 24, no. 31-32, pp. 5881–5895, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. F. Martinon, P. Brochard, M. Ripaux et al., “Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus,” Vaccine, vol. 26, no. 4, pp. 532–545, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. N. P. Goonetilleke, H. McShane, C. M. Hannan, R. J. Anderson, R. H. Brookes, and A. V. S. Hill, “Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara,” Journal of Immunology, vol. 171, no. 3, pp. 1602–1609, 2003. View at Google Scholar · View at Scopus
  40. S. Lu, “Heterologous prime-boost vaccination,” Current Opinion in Immunology, vol. 21, no. 3, pp. 346–351, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. L. Ba, C. E. Yi, L. Zhang, D. D. Ho, and Z. Chen, “Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus,” Applied Microbiology and Biotechnology, vol. 76, no. 5, pp. 1131–1136, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Liu, Q. Zhong, T. Tian, K. Dubin, S. K. Athale, and T. S. Kupper, “Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity,” Nature Medicine, vol. 16, no. 2, pp. 224–227, 2010. View at Publisher · View at Google Scholar · View at Scopus